Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - United Therapeutics Corp. (NasdaqNM:UTHR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 10Earnings Announcement
Aug  8Price hit new 52-week low ($8.78)
Location
1110 Spring Street
Silver Spring, MD 20910
Phone: (301) 608-9292
Fax: (301) 608-9291
Employees (last reported count): 110
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 55%
·Institutional: 64% (143% of float)
(146 institutions)
·Net Inst. Buying: 449.0K shares (+3.33%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
United Therapeutics Corp. is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services. Pharmaceutical products include Remodulin, which the Company is developing for treating advanced pulmonary hypertension and late-stage peripheral vascular disease and Beraprost, which is for the treatment of peripheral vascular disease. Pulmonary hypertension patients require periodic monitoring of certain bodily measurements such as heart and lung function. Much of this monitoring can be achieved with less expense and inconvenience by using telemedicine devices that enable physicians to monitor patients remotely. United Therapeutics intends to provide telemedicine services for a fee to patients and physicians using and prescribing United Therapeutics' products.
More from Market Guide: Expanded Business Description

Financial Summary
UTHR is a pharmaceutical company focused on clinical development and commercialization of in-licensed compounds for the treatment of life-threatening diseases characterized by high chronic care costs. For the six months ended 6/30/01, revenues totaled $2.8 million, up from $856 thousand. Net loss fell 45% to $20 million. Revenues reflect an increase in resales of pumps and supplies to distributors. Lower losses reflect decreased R&D expenses for acquired products and products rights.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Martine Rothblatt, 46
Chairman and CEO
$354K
Roger Jeffs, Ph.D., 39
Pres, COO
335K
Fred Hadeed, 36
CFO
--  
Gilles Cloutier, Ph.D., 56
Exec. VP Special Projects
287K
Shelmer Blackburn, Jr., 40
Exec. VP of Medical Affairs, Sec., Director
244K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:UTHRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 8-Aug-2001
$8.78 
Recent Price$13.50 
52-Week High
on 2-Oct-2000
$88.625
Beta-0.83 
Daily Volume (3-month avg)255.7K
Daily Volume (10-day avg)156.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-84.4%
52-Week Change
relative to S&P500
-79.1%
Share-Related Items
Market Capitalization$273.4M
Shares Outstanding20.3M
Float9.10M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$10.55 
Earnings (ttm)-$2.91 
Earnings (mrq)-$0.53 
Sales (ttm)$0.20 
Cash (mrq)$8.06 
Valuation Ratios
Price/Book (mrq)1.28 
Price/EarningsN/A 
Price/Sales (ttm)68.48 
Income Statements
Sales (ttm)$3.99M
EBITDA (ttm)-$65.7M
Income available to common (ttm)-$58.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-26.86%
Return on Equity (ttm)-28.59%
Financial Strength
Current Ratio (mrq)14.44 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$163.3M
Short Interest
As of 8-Aug-2001
Shares Short1.92M
Percent of Float21.1%
Shares Short
(Prior Month)
1.23M
Short Ratio4.29 
Daily Volume447.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.